Plain-English translation of NCT05145400 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three medications—, , and (called Isa-Rd)—given together at lower doses than usual. The study focuses on older adults and patients who are too frail or medically vulnerable to tolerate the standard, stronger treatments typically used for newly diagnosed multiple myeloma. The goal is to find a treatment that works well while causing fewer or less serious side effects.
Many older patients and those with significant health problems cannot safely receive the standard intensive treatments for multiple myeloma because these treatments are too harsh on their bodies. This trial exists to find out whether using this three-drug combination at lower doses can help these vulnerable patients fight their cancer effectively while keeping them safer and maintaining their quality of life.
You likely qualify if…
You likely don't qualify if…
You will receive the three-medication combination in 28-day treatment cycles. The medication and will be given as ongoing treatment, while will be given weekly for the first 8 cycles. You will continue treatment for up to about 2 years, unless your cancer stops responding or you experience unacceptable side effects. Throughout the study, you'll have regular visits to check your health, blood tests to monitor your cancer and how you're responding, and assessments of your overall well-being and quality of life.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States